The long-held promise of a cheaper, generic insulin is starting to come to fruition.
High insulin prices are a hot topic with drug-price advocates, lawmakers, regulators, and President Donald Trump. High prices have created serious financial strain on the tens of millions of Americans with diabetes. Countless testimonies describe patients dying because they rationed their insulin due to its cost.
Starting in March 2020, insulin will fall under a narrower definition; namely “biologic,” making it easier to create a substitutable generic and drive down insulin costs, FDA leader Scott Gottlieb said Dec 11.
Creating a cheaper, substitutable version of insulin ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.